Tissue plasminogen activator is required for the growth, invasion, and angiogenesis of pancreatic tumor cells

Gastroenterology

Volumn 122, Issue 3, 2002, Pages 806-819

  Díaz, Víctor M ^a,b   Planagumà, Jesús ^a   Thomson, Timothy M ^a,b   Reventós, Jaume ^a   Paciucci, Rosanna ^a  

^a Hospital Materno Infantil   (Spain)

^b CSIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; KI 67 ANTIGEN; TETRACYCLINE; TISSUE PLASMINOGEN ACTIVATOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER INVASION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MITOGENESIS; MITOSIS; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS TUMOR; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH;

EID: 0036176560     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2002.31885     Document Type: Article

References (52)

1. Physiological consequences of loss of plasminogen activator gene function in mice
2. Tumor invasion and the extracellular matrix
3. Proteases and protease inhibitors in tumor progression
4. Urokinase generated plasmin activates matrix metalloproteinases during aneurysm formation
5. Plasminogen activators, tissue degradation, and cancer
6. Plasminogen activator dependent pathways in the dissemination of human tumor cells in the chick embryo
7. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor
8. Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA
9. Characterization of the activation of latent TGF-beta by co-cultures of endothelial cells and pericytes or smooth muscle cells: A self-regulating system
10. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms
11. Role of extracellular matrix in the action of basic fibroblast growth factor: Matrix as a source of growth factor for long-term stimulation of plasminogen activator production and DNA synthesis
12. Role of insulin-like growth factor binding protein-2 and its limited proteolysis in neuroblastoma cell proliferation: Modulation by transforming growth factor beta and retinoic acid
13. The urokinasetype plasminogen activator system in cancer metastasis: A review
14. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)deficient and wild-type mice: Cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals
15. Polyoma middle T-induced vascular tumor formation: The role of the plasminogen activator/plasmin system
16. Plasminogen activators and inhibitor type I in neoplastic colonic tissue from patients with familial adenomatous polyposis
17. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: A prospective study on multicenter basis
18. The secretion of plasminogen activators by human myeloid leukemic cells in vitro
19. The plasminogen-plasminogen activator (PA) system in neuroblastoma: Role of PA inhibitor-1 in metastasis
20. Isolation of tissue-type plasminogen activator, cathepsin H, and non-specific cross-reacting antigen from SK-PC-1 pancreas cancer cells using subtractive hybridization
21. The plasminogen activator system in pancreas cancer: Role of t-PA in the invasive potential in vitro
22. Retinoic acid-enhanced invasion through reconstituted basement membrane by human SK-N-SH neuroblastoma cells involves membrane-associated tissue-type plasminogen activator
23. Biochemical and functional characterization of human tissuetype plasminogen activator variants with mutagenized kringle domains
24. Effects of antisense oligonucteotides directed toward dihydrofolate reductase RNA in mammalian cultured cells
25. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
26. Growth factors rapidly induce expression of the glucose transporter gene
27. Soft agar growth assays for transforming growth factors and mitogenic peptides
28. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma
29. Tissue type plasminogen activator is a potent mitogen for human aortic smooth muscle cells
30. Urokinase-type and tissue-type plasminogen activators as growth factors of human fibroblasts
31. Inhibition of tissue-plasminogen activator by benzamidine derivatives
32. An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II
33. Correlation of patterns of anchorage-independent growth with in vivo behavior of cells from a murine fibrosarcoma
34. Indispensable role of tissue-type plasminogen activator in growth factor-dependent tube formation of human microvascular endothelial cells in vitro
35. Expression of tissue-type plasminogen activator and its inhibitor couples with development of capillary network by human microvascular endothelial cells on Matrigel
36. Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways
37. Plasminogen activators and angiogenesis
38. Urokinase and tissue-type plasminogen activator are required for the mitogenic and chemotactic effects of bovine fibroblast growth factor and platelet derived growth factor-BB for vascular smooth muscle cells
39. Tissue plasminogen activator increases canine enclothelial cell proliferation rate through a plasmin-independent, receptor-mediated mechanism
40. Intestinal.tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin
41. In vivo evidence that stromelysin-3 metalloproteinase contribute in a paracrine manner to epithelial cell malignancy
42. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis
43. Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice
44. Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line
45. Mechanisms of angiodenesis and arteriogenesis
46. Activation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreas tumor cells overexpressing Met
47. Cell lines of the human and rodent exocrine pancreas
48. Maspin is an angiogenesis inhibitor
49. Tissue-type plasminogen activator is a target of the tumor suppressor gene maspin
50. Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation
51. Plasminogen/plasminogen activator and growth factor activation
52. Epithelial cell plasticity in development and tumor progression